Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $43.17

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $43.17.

Several research firms recently issued reports on ORKA. Wedbush reissued an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Finally, Stifel Nicolaus started coverage on Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price target for the company.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $144,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the third quarter worth $343,000. The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics in the third quarter valued at about $1,037,000. Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $2,013,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Oruka Therapeutics in the third quarter worth about $5,840,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $12.19 on Tuesday. Oruka Therapeutics has a fifty-two week low of $11.95 and a fifty-two week high of $53.88. The business has a fifty day moving average of $19.10. The firm has a market capitalization of $426.64 million, a PE ratio of -1.95 and a beta of 0.81.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.